Transfusions of the experimental composition were effective in 90% of cases in patients with hemophilia. In just a year, this experiment may become a reality, entering into widespread clinical practice.
Hematologists at University College London have developed a miracle injection that can cure a type of hemophilia. We are talking about people who suffer from the so-called version B of this disorder, in which a person has very significant bleeding even with the smallest cuts and injuries. Currently, these patients require regular injections of factor IX, a blood-clotting protein that they have been missing since birth.
Monoclonal antibodies reduce the severity of hemophilia
And now a one-time treatment has been developed that can completely transform the quality of life of such patients. With it, their body learns to naturally reproduce the missing protein. One patient who received an experimental injection (a type of gene therapy) claims that his life is now completely normal. And this makes a cure for hemophilia a reality for the vast majority of victims of this disease within one to three years.
Gene therapy has been successful in treating hemophilia
If one of us cuts ourselves, clotting factors mixed with platelets combine to thicken the blood as much as possible and stop the bleeding. But patients with hemophilia, which is divided into types A and B, lack clotting factors. For some of them, this can be a deadly phenomenon, and hemophilia also causes severe joint pain in a number of patients. There are approximately 10,000 patients in Russia with hemophilia, which tends to be inherited and mostly affects men. (READ MORE) 
University College London
Medicine
City of London University, part of composition of the University of London. Located in the heart of the capital, on Gower Street.